Intelligence · Clinical Development
Pipeline search results
Programs matching “non-small-cell-lung-cancer” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 211 pipeline programs matching "non-small-cell-lung-cancer" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
Zimberelimab
Arcus Biosciences
Non-small Cell Lung Cancer
2 trials -
bexarotene
Eisai Co.,
Non-small Cell Lung Cancer
1 trial -
brigatinib
Takeda
Non-Small Cell Lung Cancer
2 trials -
canakinumab
Novartis Pharmaceuticals
Non-small Cell Lung Cancer
2 trials -
cemiplimab
Regeneron UK Limited
Non-small Cell Lung Cancer
3 trials -
cetuximab + cisplatin + vinorelbine
Merck KGaA, Darmstadt, Germany
Non Small Cell Lung Cancer (NSCLC)
1 trial -
daraxonrasib
Revolution Medicines
NSCLC (Non-small Cell Lung Cancer)
1 trial -
erlotinib
Hoffmann-La Roche
Non-Squamous Non-Small Cell Lung Cancer
1 trial -
fianlimab
Regeneron UK Limited
Non-small Cell Lung Cancer
1 trial -
fianlimab
Regeneron UK Limited
Advanced Non-Small Cell Lung Cancer
1 trial -
furmonertinib 240 mg oral, daily
ArriVent BioPharma
Metastatic Non-Small Cell Lung Cancer
1 trial -
gemcitabine
NORTHWEST BIOTHERAPEUTICS INC
Non-Small Cell Lung Cancer
1 trial -
patients undergo cVATS segmentectomy
The First People's Hospital of Lianyungang
Non-small Cell Lung Cancer Stage I
1 trial -
pembrolizumab
Merck KGaA, Darmstadt, Germany
Non-small Cell Lung Cancer
2 trials -
AK104
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Resectable Non-small Cell Lung Cancer
1 trial -
ASP8273
Astellas Pharma Inc
Non-small Cell Lung Cancer
1 trial -
AZD9291
Samsung Bioepis NL B.V.
Non-Small Cell Lung Cancer With EGFR T790M Mutation
1 trial -
Aglatimagene besadenovec
Candel Therapeutics
Non Small Cell Lung Cancer
1 trial -
Alirocumab
Regeneron UK Limited
Non Small Cell Lung Cancer
1 trial -
Alirocumab and Cemiplimab
Regeneron UK Limited
Non-small Cell Lung Cancer (NSCLC)
1 trial -
Alkotinib Capsules
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
ALK-positive Non-small Cell Lung Cancer
1 trial -
Almonertinib
The First People's Hospital of Lianyungang
EGFR Positive Non-small Cell Lung Cancer
1 trial -
Almonertinib
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Non-small Cell Lung Cancer
1 trial -
Almonertinib
The First People's Hospital of Lianyungang
Non Small Cell Lung Cancer
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.